For 12 years, there’s been a raging, multibillion-dollar controversy in the giant market for cholesterol-lowering drugs taken by 20 million or more Americans: do one set of pills, Zetia and Vytorin from Merck, actually prevent heart attacks or are the pills, in the memorable words of one top cardiologist, expensive placebos? That controversy turned into a maelstrom after Merck’s then partner, Schering-Plough, seemed to try to bury a negative – but preliminary – study. The controversy that caused use of the medicines to drop more than 60% and sales to drop 25% (Merck’s price increases explain the difference between those numbers.)
Hey, check out all the research scientist jobs. Post your resume today!
